Performance-Based Risk-Sharing Arrangements: An Updated International Review

PharmacoEconomics

Volumn 35, Issue 10, 2017, Pages 1063-1072

  Carlson, Josh J ^a   Chen, Shuxian ^a   Garrison, Louis P ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADOPTION; AUSTRALIA; HUMAN; PERFORMANCE; PRIORITY JOURNAL; REIMBURSEMENT; REVIEW; RISK MANAGEMENT; SWEDEN; TAXONOMY; UNITED KINGDOM; UNITED STATES; INTERNATIONAL COOPERATION; ORGANIZATION AND MANAGEMENT; TRENDS;

HUMANS; INTERNATIONALITY; RISK SHARING, FINANCIAL;

EID: 85022178314     PISSN: 11707690     EISSN: 11792027     Source Type: Journal    
DOI: 10.1007/s40273-017-0535-z     Document Type: Review

References (26)

1. Carlson JJ, Sullivan SD, Garrison LP, Neumann PJ, Veenstra DL. Linking payment to health outcomes: a taxonomy and examination of performance-based reimbursement schemes between healthcare payers and manufacturers. Health Policy. 2010;96(3):179–90. doi:10.1016/j.healthpol.2010.02.005.
2. de Pouvourville G. Risk-sharing agreements for innovative drugs: a new solution to old problems? Eur J Health Econ. 2006;7(3):155–7.
3. Espin J, Rovira J, Olry de Labry A. WHO/HAI Project on Medicine Prices and Availability. Review Series on Pharmaceutical Pricing Policies and Interventions. Working Paper 1: external reference pricing. Granada: Andalusian School of Public Health; 2011.
4. NICE. List of technologies with approved Patient Access Schemes. 2017. https://www.nice.org.uk/about/what-we-do/patient-access-schemes-liaison-unit/list-of-technologies-with-approved-patient-access-schemes. Accessed 8 Mar 2017.
5. Garrison LP Jr, Carlson JJ, Bajaj PS, Towse A, Neumann PJ, Sullivan SD, et al. Private sector risk-sharing agreements in the United States: trends, barriers, and prospects. Am J Manag Care. 2015;21(9):632–40.
6. The University of Washington Performance Based Risk Sharing (PBRS) web-enabled database [database on the Internet]. 2017. https://depts.washington.edu/pbrs/. Accessed 10 Mar 2017.
7. Walker S, Sculpher M, Claxton K, Palmer S. Coverage with evidence development, only in research, risk sharing, or patient access scheme? A framework for coverage decisions. Value Health. 2012;15(3):570–9. doi:10.1016/j.jval.2011.12.013.
8. Louis P, Garrison J, Towse A, Briggs A. Performance-based risk-sharing arrangements—good practices for design, implementation, and evaluation: ISPOR good practices for performance-based risk-sharing arrangements task force report. Value Health. 2013;16(5):703–19.
9. CMS. CMS coverage with evidence development. 2017. https://www.cms.gov/Medicare/Coverage/Coverage-with-Evidence-Development/index.html. Accessed 7 Mar 2017.
10. TLV. Beslut läkemedel. 2017. http://www.tlv.se/beslut/beslut-lakemedel/. Accessed 8 Mar 2017.
11. AIFA. Lista aggiornata dei Registri e dei Piani Terapeutici web based. 2017. http://www.agenziafarmaco.gov.it/it/content/lista-aggiornata-dei-registri-e-dei-piani-terapeutici-web-based. Accessed 8 Mar 2017.
12. ZonWm. Programma: Doelmatigheidsonderzoek Farmacotherapie. 2017. https://www.zonmw.nl/nl/onderzoek-resultaten/geneesmiddelen/programmas/programma-detail/doelmatigheidsonderzoek-farmacotherapie/. Accessed 8 Mar 2017.
13. PBS. Pharmaceutical Benefit Advisory Committee outcomes. 2017. http://www.pbs.gov.au/info/industry/listing/elements/pbac-meetings/pbac-outcomes/. Accessed 8 Mar 2017.
14. Lu CY, Williams KM, Day RO. The funding and use of high-cost medicines in Australia: the example of anti-rheumatic biological medicines. Aust N Z Health Policy. 2007;4:2.
15. Vitry A, Roughead E. Managed entry agreements for pharmaceuticals in Australia. Health Policy. 2014;117(3):345–52. doi:10.1016/j.healthpol.2014.05.005.
16. Neumann PJ, Chambers J. Medicare’s reset on ‘coverage with evidence development’. Health Affairs Blog. 2013 Apr 1. http://healthaffairs.org/blog/2013/04/01/medicares-reset-on-coverage-with-evidence-development/. Accessed 2 Jul 2017.
17. Neumann PJ, Kamae MS, Palmer JA. Medicare’s national coverage decisions for technologies, 1999–2007. Health Aff (Millwood). 2008;27(6):1620–31. doi:10.1377/hlthaff.27.6.1620.
18. Carlson JJ, Gries KS, Yeung K, Sullivan SD, Garrison LP Jr. Current status and trends in performance-based risk-sharing arrangements between healthcare payers and medical product manufacturers. Appl Health Econ Health Policy. 2014;12(3):231–8. doi:10.1007/s40258-014-0093-x.
19. FDA. FDA approves new drug to treat heart failure. 2015. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm453845.htm. Accessed 15 Feb 2017.
20. FDA. FDA approves Repatha to treat certain patients with high cholesterol. 2015. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm460082.htm. Accessed 15 Feb 2017.
21. Drummond M. When do performance-based risk-sharing arrangements make sense? Eur J Health Econ. 2015;16(6):569–71. doi:10.1007/s10198-015-0683-z.
22. CMS. Medicare Program; Part B drug payment model, a proposed rule by the Centers for Medicare & Medicaid Services. 2016. https://www.federalregister.gov/documents/2016/03/11/2016-05459/medicare-program-part-b-drug-payment-model. Accessed 8 Mar 2017.
23. Launois R, Navarrete LF, Ethgen O, Le Moine JG, Gatsinga R. Health economic value of an innovation: delimiting the scope and framework of future market entry agreements. J Mark Access Health Policy. 2014;2.
24. Edlin R, Hall P, Wallner K, McCabe C. Sharing risk between payer and provider by leasing health technologies: an affordable and effective reimbursement strategy for innovative technologies? Value Health. 2014;17:438–44.
25. Towse A, Pistollato M, Mestre-Ferrandiz J, Khan Z, Kaura S, Garrison L. European union pharmaceutical markets: a case for differential pricing? Int J Econ Bus. 2015;22(2):263–75.
26. Kaló Z, Annemans L, Garrison LP. Differential pricing of new pharmaceuticals in lower income European countries. Expert Rev Pharmacoecon Outcomes Res. 2013;13(6):735–41.